MedPath

Evaluation of an antimalaria combined with praziquantel for treating Kenya children with intestinal or urogenital bilharzia in Homabay County

Phase 3
Conditions
schistosomiasis
Registration Number
PACTR202211501227743
Lead Sponsor
Kenya Medical Research Institute
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
702
Inclusion Criteria

•Aged between 6 and 15 years old (confirmed from the date of birth recorded on the school registers),
•Study participants appear healthy at enrollment, as assessed by the study clinician
• Suffering from S. mansoni or S. haematobium infection
•Residing in Homabay county
•Able to take oral treatment,
•Respective parent/ guardian gives informed consent for the child to participate in the study
•Child assent to participate in study

Exclusion Criteria

•Weighing more than 50 kg,
•Pregnant or lactating at the time of the study,
•Presence of infection with Plasmodium falciparum or other Plasmodium spp.
•Presence of severe illness, such as cerebral cysticercosis,
•Signs of severe malnutrition
•Hypersensitivity to Artesunates, sulfonamides or praziquantel.
•Use of another anti-malaria or anti-schistosomal drug during the study, or within 28 days before the administration of the study treatment.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath